Highlights Aligned with the FDA in two Positive Type C meetings supporting key elements of the planned Phase 3 program for ATH434 in MSAAdvancing ...

Alignment reached on chemistry, manufacturing, and control (CMC) elements of ATH434 Phase 3 development program – – Positive feedback supports ...

Alterity Therapeutics ( (AU:ATH) ) has provided an announcement.

Alterity Therapeutics (NASDAQ: ATHE) shares are trading lower on Wednesday. This is a potential sell-off after the stock increased over 200% yesterday following the company announcing it will present ...

The average one-year price target for Alterity Therapeutics Limited - Depositary Receipt (NasdaqCM:ATHE) has been revised to $4.27 / share. This is a decrease of 35.66% from the prior estimate of ...

The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But when you pick a company that is really flourishing, you can make more than 100%. For example, the ...

Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate future for people living with neurodegenerative diseases. The Company is focused on developing ...

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today ...

The average one-year price target for Alterity Therapeutics Limited - Depositary Receipt (NasdaqCM:ATHE) has been revised to $3.98 / share. This is an increase of 18.07% from the prior estimate of $3.

Alterity announces board changes ahead of its AGM, positioning biotech for next growth phase Founding shareholder, former CEO and current non-executive chairman Geoffrey Kempler retires CEO Dr David ...

Alignment reached on chemistry, manufacturing, and control (CMC) elements of ATH434 Phase 3 development program - - Positive feedback supports readiness for Phase 3 initiation with manufacturing ...